Abstract. The lack of reliable early detection of ovarian cancer and the absence of specific symptoms result in diagnosis of ovarian cancer at advanced stage in the majority of the patients.
Introduction
Epithelial cancer of the ovary is the sixth most common cancer in women and is the leading cause of death from a gynaecological malignancy (1) . The lack of reliable methods of early detection and the absence of specific symptoms result in late stage at diagnosis in the majority of the patients (70%). The 5-year survival for patients with early disease [International Federation of Gynecology and Obstetrics (FIGO) stages I/II] differs from that of patients with advanced disease (FIGO stages III/IV) (2) and little progress has been made over the past decades to improve long-term survival (3) .
We conducted expression profiling of 26 serous epithelial ovarian tumor samples obtained from 24 patients, and tissue from 7 normal ovary samples, using cDNA microarrays spotted with 19,200 known genes and Expressed Sequence Tags (ESTs), and used SAM (significance analysis of microarrays) (4) to reveal genes differentially expressed in SEOC as compared to normal ovaries. logical stage (Table I) . Samples were included from both the primary 'A sample' and metastatic 'B sample' sites in two cases (OCA23A/B and OCA27A/B). Snap-frozen tissue samples from five normal ovaries from women undergoing oophorectomy for non-neoplastic conditions were also included. The clinical data on all patients are summarized in Table I . Following procedures well-established in our centre, all tissue samples were snap-frozen in liquid nitrogen after surgical resection and stored at -80˚C. RNA samples extracted from the ovaries of healthy donors were purchased from two sources (Stratagene, La Jolla, CA, USA; and Ambion, Austin, TX, USA). Finally, ovarian surface epithelial scrapings were obtained from four patients undergoing pelvic surgery for indications other than ovarian cancer. Because of the very low yield of epithelial scrapings, we were unable to obtain a sufficient quantity of normal ovarian surface epithelium to conduct microarray experiments.
RNA extraction. RNA was extracted from tissue samples as previously described (5) . RNA quality and concentration were verified using an Agilent Bioanalyzer (Agilent BioTechnologies, Palo Alto, CA).
Microarray experiments. Ovarian tumor total-RNA (10 μg), normal ovary total-RNA or Human Universal Reference (HUR) RNA (prepared from a pool of 10 cell lines, Stratagene), were reverse transcribed with Superscript II reverse transcriptase (Invitrogen Canada, Burlington, ON) while incorporating Cy3-or Cy5-dCTP (NEN, Boston, MA). The fluorescently labeled cDNAs were co-hybridized overnight at 37˚C to 19K version 2 and 3 microarrays manufactured at the University Health Network Microarray Centre and spotted in duplicate with 19,200 cDNA fragments. A complete list of the cDNA collection used for these arrays (Human 19.2K) can be found at the University Health Network Microarray Centre web site (http://www.microarrays.ca). The microarrays were read by a confocal laser reader (ScanArray 4000, Packard BioScience, Meriden, CT) after stringent washings. We used the GenePix Pro 3.0 (Axon Instruments, Foster City, CA) image analysis software to quantify the scanned images. Low quality spots were filtered as identified by GenePix Pro 3.0 as well based on visual examination of the images.
Microarray data analysis
Initial data processing. Data warehousing, filtering and normalization were performed using the GeneTraffic software (version 2.6, Iobion, Stratagene). All hybridizations were annotated according to the MIAME (Minimum Information About a Microarray Experiment) guidelines [http://www. mged.org/Workgroups/MIAME/miame.html and in Brazma et al (6) ]. Briefly, each of the 33 samples was assayed with two dye reversal microarray hybridizations (except one sample for which only one hybridization was successful) for a total of 65 hybridizations. Dye reversal replicate hybridizations were used to control for potential labeling differences. The UHN Human 19K microarray used included 38,400 spots corresponding to 18,114 unique spotted cDNA clones. The initial data set was filtered to exclude spots flagged in the quantification process, spots whose raw intensity was less than the local background in either of the two channels, spots which had a spot to background ratio of <1, and spots whose raw intensity was <100. LOWESS (Locally Weighted Scatter Plot Smoother) normalization by sub-array (http://stat-www. berkeley.edu/users/terry/zarray/Html and GeneTraffic 2.0 Manual, Iobion, Stratagene) was used for normalization of all microarrays. A Master 'spot ratio' table (MST) was exported from GeneTraffic with the mean normalized log2 ratio (sample vs. HUR) recorded for each unique clone ID (spot) and each unique hybridization (slide); in this table the  flagged spots appear as missing values. A Master 'gene ratio'  table (MGT) was generated by GeneTraffic from the Master  Spot ratio table MST, by averaging all spot ratios  corresponding to the same clone IDs on the arrays and Table I. Histopathological data of EOC patients and normal  ovaries.  -------------------------------------------------Patient sample  Type  Stage  Grade  -------------------------------------------------OVD12  Ser Pap  I  2  OVD15  Ser Pap  I  3  OCA19  Ser Pap  II  3  OVD16  Ser Pap  II  3  OVD17  Ser Pap  II  3  OVS1  Ser Pap  II  2 Non
Ser Pap, serous papillary; Non-Ca, normal (non-cancerous) ovarian tissue; Tumor stage is given according to the International Federation of Gynecology and Obstetrics criteria, tumor allocation is based on stage.
averaging all hybridizations corresponding to the same patient samples. The missing values (from flagged spots) were estimated by 10-nearest-neighbor imput.
'Tumor versus normal' study: unsupervised analysis. Unsupervised analysis comparing tumor samples to normal ovarian tissue was carried out on the gene ratio tables derived from MGT. The sub data set was median-centered and then analyzed by two-dimensional hierarchical clustering using the Cluster by Eisen Lab (http://rana.lbl.gov/EisenSoftware. htm) software. Average-linkage clustering using a Pearson correlation (uncentered) metric was applied to both the gene and sample dimension (7) . The result of this unsupervised analysis are two dendrograms; one indicating the similarity between samples and the other indicating the similarity between genes. This hierarchical cluster was visualized in TreeView (http://rana.lbl.gov/EisenSoftware.htm) as a 2D 'heat map'. In the 2D view the genes and cell lines are ordered according to their position in the dendrogram hierarchy, while the color at each position indicates the level of gene expression of each sample relative to the median level of expression.
'Tumor versus normal' study: supervised analysis. Supervised analysis was carried out on the first sub-data set derived from the MST, i.e. at the spot ratio level, in order to increase the statistical power of the data set by treating each hybridization and each spot independently. In order to identify genes that were differentially expressed in EOC as compared to normal ovarian tissue, the samples were divided into two groups, normal ovaries (n=7) and tumor samples (n=26) and processed with a two-class statistical analysis of microarrays (SAM) analysis (4) . SAM employs a modified t-test to identify differentially expressed genes and estimates the false discovery rate (FDR) by a permutation analysis. In the present analysis, 370 clones were identified (corresponding to 329 unique genes) as being differentially expressed, with a 4.2% FDR. These clones were then resolved using hierarchical clustering as described above, and visualized using a 2D heat map.
Quantitative real-time RT-PCR. DNaseI (1 μg) treated total-RNA from ovarian tumors and normal ovaries (or 0.1-1 μg from ovarian epithelial scrapings) was reverse transcribed in a 100-μl reaction mixture containing 1X room temperature buffer, 5.5 mM MgCl 2 , 500 μM each dNTP, 2.5 μM random hexamers, 0.4 units/μl RNase inhibitor, and 3.125 units/μl MultiScribe Reverse Transcriptase (Applied Biosystems, Foster City, CA) in the following conditions: 25˚C for 10 min, 48˚C for 60 min, and 95˚C for 5 min. Real-time relative quantitative PCR was performed in triplicate using the ABI PRISM 7900HT Sequence Detection system (Applied Biosystems) according to the manufacturer's instructions, and data were averaged. Primers were specifically designed for each of four genes: WAP four-disulfide core domain protein HE4 (WAP), secreted phosphoprotein 1 (SPP1, osteopontin), decorin (DCN) and human peptidylprolyl isomerase A (cyclophilin A, PPIA); using Primer Express v1.5a (Applied Biosystems). The following primers were used: a) decorin: 5'-GCC AGA AAA AAT GCC CAA AAC-3' (forward primer), 5'-AGT AAC TTT TCG CAC TTT GGT GAT C-3' (reverse primer); b) osteopontin: 5'-CGT CTC AGG CCA GTT GCA-3' (forward primer), 5'-GTG ATG CCT AGG AGG CAA A-3' (reverse primer); c) WAP four-disulfide core domain 2: 5'-CAG GTG GAC AGC CAG TGT-3' (forward primer), 5'-GGA CCT CAG AAA TTG GGA GTG A-3' (reverse primer); d) human cyclophilin A: 5'-TGC TGG ACC CAA CAC AAA TG-3' (forward primer), 5'-TGC CAT CCA ACC ACT CAG TC-3' (reverse primer). Of each cDNA (0.4 μl) was amplified using SYBR ® Green PCR Master Mix. TaqMan Assay-On-Demand (Applied Biosystems) was used for activin A receptor, type I (ACVR1); tumor necrosis factor (TNF superfamily, member 2; TNF) and human peptidylprolyl isomerase A (cyclophilin A, PPIA). Both SYBR Green PCR and TaqMan ® assays were carried out with the following PCR conditions: 50˚C for 2 min, 95˚C for 10 min, followed by 40 cycles of 95˚C for 15 sec and 60˚C for 1 min. Human cyclophilin A was used as an endogenous control because it resulted in minimum variation throughout the samples and has been used by other investigators analyzing gene expression using real-time RT-PCR [e.g., by Trogan et al (8) ]. Each threshold cycle (C T ), which indicates the cycle at which an increase in reporter fluorescence goes slightly over the optimal value line, was determined. The C T value of human cyclophilin A was subtracted from each C T value of tumor, normal tissue and ovarian epithelial scrapings for normalization and the ratio of sample to human universal reference (Stratagene) expression was calculated to compare with microarray data. All realtime products were run on the Agilent 2100 Bioanalyzer (Agilent Technologies) on the DNA 500 Assay lab chip to confirm a single product formation and amplicon size. The 1-tailed t-test was used to examine the significant difference of gene expression ratios between groups of ovary scrapings, normal and tumors. Statistical significance was defined as p<0.05.
Results
In this study, we performed microarray data analysis in two sequential phases. First, we used unsupervised analysis of the complete data set using two-dimensional hierarchical clustering to look at the overall gene expression profiles of SEOC samples with respect to normal ovary tissue, and second, we carried out a statistical analysis of the same complete data set using SAM [Tusher et al (4) and http://www-stat.stanford. edu/~tibs/SAM/] to identify those genes showing statistically significant differential expression between normal ovaries and SEOC.
SAM is a powerful statistical technique for finding genes significantly differentially expressed in a series of microarray experiments. The pre-processed (i.e., flagged, filtered and normalized) microarray data obtained for a set of samples are entered, and a response variable is chosen for each sample. The algorithm uses repeated permutations of the data to identify those genes whose expression is significantly related to SEOC. The significance cut-off can be chosen, through the selection of a false discovery rate (FDR).
To ascertain the validity of our microarray methodology, and to identify novel genes potentially implicated in SEOC, we first profiled the expression of the whole cohort of 33 samples, by unsupervised average-linkage two-dimensional hierarchical clustering, using a common reference (Human Universal Reference, Stratagene). In order to avoid possible ONCOLOGY REPORTS 18: 1347 -1356 , 2007 data contamination or bias introduced by the use of normal ovary RNA as a reference, we used the internal reference HUR RNA described above in all microarray experiments. This approach has been commonly used in microarray studies (9) (10) (11) (12) (13) (14) (15) to allow the determination of global relative gene expression profiles in multiple samples and is an invaluable tool for tumor classification.
The dendrogram representing the overall degree of similarity in samples expression profiles is displayed in Fig. 1A and shows that the 33 ovarian samples studied here separate into 2 main groups based on their microarray expression profiles. The first cluster contains exclusively tumor samples with a larger proportion of advanced stage SEOC samples (8 advanced samples, 4 early samples). The second cluster of samples contains both tumor samples and normal ovary samples, with 4 (all tissue samples) out of 7 normal ovarian samples clustering together as a group. Universal reference samples clustered with advanced stage cancers.
To identify subsets of genes that show significant differential expression between normal and ovarian tumors, we carried out a supervised statistical analysis on the same data set separated into 2 groups, normal ovaries (group N), and SEOC samples (group T). Two-class SAM analysis identified 370 differentially expressed clones and ESTs at a false discovery rate of 4.2%. We then used hierarchical clustering to resolve the differential expression of the samples over these 370 differentially expressed clones (Fig. 1B) . This clustering demonstrates, as expected, a clear separation of normal ovary samples from tumor samples. Out of these 370 clones, 234 unique genes showed a differential expression >1.3 times between normal ovaries and SEOC, with down-regulation in tumor samples observed for 144 unique genes, and upregulation in tumor samples was observed for 90 unique genes. A partial list of these differentially expressed genes is presented in Table II . In addition to previously reported genes, such as the two WAP four-disulfide core domain proteins HE4 and SPL (16) (p=0.005; Fig. 2 ), osteopontin (17) (p=0.0024; Fig. 2 ), decorin (5) (p=0.0087; Fig. 2) , and several ribosomal proteins (Table II) , we also identified several genes, which to the best of our knowledge have not been previously reported in expression analysis of human ovarian cancer tissues. Of particular interest among the newly identified genes, is the up-regulation of tumor necrosis factor α (TNFα; p=0.0001; Fig. 2 ) concurrent with the downregulation of decorin (p=0.0087; Fig. 2 ).
Five genes were selected for further validation on the basis of their gene expression differences combined with available literature of the genes in ovarian cancer (16) (17) (18) (19) (20) . Real-time RT-PCR was used to measure and compare the expression levels of these 5 selected genes: WAP four-disulfide core Table II . Genes statistically differentially expressed between SEOC and normal ovarian tissue. domain protein HE4 (WAP, up-regulated), secreted phosphoprotein 1 (SPP1, osteopontin; up-regulated), activin A receptor, type I (ACVR1; up-regulated), tumor necrosis factor (TNF superfamily, member 2; TNF, up-regulated) and decorin (DCN, down-regulated) in 4 epithelial scrapings and in 6 bulk-extracted normal ovaries. The results obtained (Fig. 2) show that for the up-regulated genes the expression levels measured by real-time RT-PCR did not differ significantly between normal ovarian epithelial scrapings and bulk-extracted ovaries. Decorin however, showed a statistically significant difference (p=0.0073) in expression between epithelial scrapings and bulk-extracted ovaries. Decorin is a member of the small leucine-rich proteoglycan superfamily and is involved in the regulation of several important cellular functions, such as matrix assembly and cell proliferation and migration.
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, relative average expression ratio of SEOC versus normal ovaries. The SAM score is the T-statistic value and indicates significance.
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Discussion
Little is known of the molecular changes that are associated with the development from normal ovarian tissue to invasive ovarian cancer. No lesion is clinically recognized that immediately precedes ovarian cancer. The late onset of symptoms (in patients with invasive cancers) makes early detection difficult. Surface epithelial tumors account for 50-55% of all ovarian tumors, and their malignant forms account for approximately 90% of all ovarian cancers in the western world. A number of well-characterized genes, differentially expressed between normal ovaries and SEOC, have been reported in the literature (5, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . In the present study we used gene expression profiling to reveal differential gene expression between SEOC and normal ovarian tissue (bulk and surface epithelial scrapings).
Several of the genes identified here have been previously reported in the literature by us (5) and others (17, 20, (26) (27) (28) (29) (30) (31) (32) and these findings provide strong experimental support for this microarray design and analytical strategy. Since we used bulk-extracted normal ovary tissue for comparison to the ovarian cancer samples, these tissues contributed considerably and possibly confounding cellular heterogeneity to the analysis. Therefore while the genes identified in the present study are relatively up-or down-regulated compared to normal ovarian tissue, their differential expression might partially reflect the differences in cell populations. Ovarian epithelial cell scrapings have been used by some investigators to generate more homologous reference RNA (22, 28, 33) , but that approach requires access to a large number of normal ovaries. The yield of ovarian surface epithelial cells is relatively low and very often unsatisfactory for microarray use. Linear PCR techniques are being used to address this issue but they appear to be challenging and have variable reliability (34, 35) .
Although a large part of the normal ovary consists of a stromal component, this stroma is very scant with cells. Hence most of the normal bulk-extracted ovary will resemble the expression profile of epithelial scrapings. We have chosen to perform our analysis on bulk-extracted ovaries and surface epithelial cells rather than cultured epithelial cells or immortalized cells as previous studies have shown that culturing and immortalizing ovarian epithelial cells can influence their gene expression (33) . Bulk-extracted ovarian tissue contains a mixture of epithelial and stromal cells whereas the majority of cells in the brushing samples are of epithelial origin only. We argue that the differences seen in our experiment between normal ovarian tissue (regardless whether its origin is bulk-extracted or epithelial scrapings) and ovarian cancer tissue are a result of malignant features of the cells.
Of the five genes that were validated by RT-PCR only decorin showed a statistically significant difference between the epithelial scrapings and bulk-extracted ovaries. Decorin has been identified as down-regulated in ovarian cancer both in microarray studies using bulk-extracted normal ovaries (5, 26) and by those using epithelial scrapings as a reference (27, 28) . Moreover, Nash et al (36) reported that decorin of ovarian tissue is made by myofibroblasts rather than by the epithelial tumor cells. The presence of stroma cell RNA in the bulk-extracted ovaries, explains our results, with expression of decorin in bulk-extracted ovaries opposed to a very low expression of decorin in epithelial scrapings. Recent studies, including by our group, have shown that decorin is down-regulated in ovarian cancer (5, 26, 28) . Since TNFα has been previously shown in vitro to down-regulate decorin gene expression (37) , the present study suggests that downregulation of decorin in SEOC might be a consequence of the up-regulation of TNFα. In addition, decorin plays a role in angiogenesis (38) and it was recently shown that decorin down-regulates the expression of VEGF in various tumor cell types (38) . Our present data demonstrating up-regulation of VEGF concurrent with a down-regulation of decorin are consistent with that observation, and suggest an important role for decorin in SEOC angiogenesis and tumor progression.
An interesting finding was disclosed when we validated the microarray results on activin A receptor type I (ACVR1). While it was up-regulated in SEOC in the microarray studies, it showed down-regulation in the validation by the RT-PCR (p=0.0164; Fig. 2 ). It is noteworthy that the activin type IA receptor expression was shown to have a high variability in serous ovarian tumors (19) . On the average, SEOC tend to have higher levels while normal ovaries tend to express lower levels, in a pattern similar to the microarray experiments. ACVR1 interacts with p120 of the inhibin receptor, that allows inhibin to bind with high affinity to the complex, which consequently destabilizes the complex and abrogates activin signal transduction (39) . Activin, along with inhibin, is a member of the TGF-ß superfamily (40) and is produced locally in the ovary (41) . It has been suggested that activin is involved in regulating cell proliferation and ovarian tumor development (18, 42) . Recently, Choi et al (43) have also shown that activin induces cell proliferation in OVCAR-3 cells but not in normal OSE cells, and these authors hypothesized that activin may be an autocrine regulator of neoplastic OSE progression.
In conclusion, our results indicate that previously uncharacterized genes are associated with the malignant phenotype of SEOC. Bulk normal ovarian tissue may serve as control for SEOC tissue in gene expression profiling. Gene expression profiling and sequential statistical analyses of gene subsets can identify new genes and molecular pathways affecting development of SEOC. In addition this approach provides additional support for emerging biomarkers with clinical applications in the future management of serous EOC.
